ReviewCurrent oncology (Toronto, Ont.)2023
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview.
Review in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Comparison of proton vs. photon radiotherapy for liver cancer: a meta-analysis.BMC gastroenterology · 2026Pooled it
- Comparative outcomes of stereotactic body radiotherapy versus radiofrequency ablation in hepatocellular carcinoma within Milan criteria: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Review
- Shrinking Giants: On the Feasibility of Downsizing Hepatocellular Carcinoma with Immunotherapy Prior to Liver Transplantation.Journal of clinical medicine · 2026Review
- Natural phenolic compounds as modulators of radiation response in hepatocellular carcinoma.Clinical and experimental medicine · 2026Review
- National survey of real-world treatment patterns for early- and intermediate-stage hepatocellular carcinoma reveals wide variation across Australian states.Internal medicine journal · 2026Article
- Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications.Portal hypertension & cirrhosis · 2026Review
- Evaluating the efficacy and immunological impact of combined ICIs and SBRT in HCC: A narrative literature review.Clinical and translational radiation oncology · 2026Review
- Patterns of care and outcome of liver SBRT: results from a multicentre National quality project.Radiation oncology (London, England) · 2026Article
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.The oncologist · 2026Article
- Vemurafenib Induces Apoptosis via JNK Activation and AKT Inhibition in Hepatocellular Carcinoma.Journal of Cancer · 2026Article
- Impact of Tumor Size on Outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA): > 3 cm Is No Absolute Contraindication.Cardiovascular and interventional radiology · 2026Article
- Advances in transarterial chemoembolization for hepatocellular carcinoma: Integration with systemic therapies and emerging treatment strategies.Cancer pathogenesis and therapy · 2026Review
- Review
- Stereotactic radiotherapy with Gamma Master SystemRadiation oncology (London, England) · 2025Article
- Report from the 26th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Hepatocellular and Biliary Tract Cancer, Saskatoon, Saskatchewan, 17-18 October 2024.Current oncology (Toronto, Ont.) · 2025Article
- Radiation Therapy Personalization in Cancer Treatment: Strategies and Perspectives.International journal of molecular sciences · 2025Review
- Leave No "Stone" Unturned: Biliary Obstruction From Isolated Intraductal Metastatic HCC.ACG case reports journal · 2025Article
- National Survey of Real-World Australian Treatment Patterns for Patients With Very-Early-To Intermediate-Stage Hepatocellular Carcinoma.Cancer medicine · 2025Article
- Sequencing microsphere selective internal radiotherapy after external beam radiotherapy for hepatocellular carcinoma: proof of concept of a synergistic combination.The British journal of radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic body radiotherapy (SBRT), a type of external beam radiotherapy, yields local control of hepatocellular carcinoma (HCC) at rates as high as 90%. SBRT has been recognized as an alternative therapy for patients for whom standard modalities such as surgery (resection or transplantation) or ablation are deemed unsuitable. SBRT has the potential to improve the prognosis of HCC, as it can be used as an adjunct to other treatment modalities. The assessment of post-SBRT images of the treated tumor and surrounding normal liver tissue requires special attention. Future research is warranted to determine how best to use SBRT versus other therapies and how to combine them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.